OR WAIT null SECS
A review of the far reaching impacts of this notoriously unreliable diagnostic test, and an evidence-based solution that is setting a new benchmark for patient care.
It is estimated that blood culture contamination results in over $1 million dollars in avoidable costs to an average-sized (250-300 bed) hospital every year. This estimate doesn’t include the impact on key Centers for Medicare and Medicaid Services (CMS) quality outcome metrics, such as the public reporting of false positive CLABSIs and MRSA bacteremia that result in associated Healthcare Associated Condition (HAC) financial penalties. So, what about a 3% blood culture contamination rate is good for the patient? Not a thing. We now have evidence that shows us the bar has been moved and this outdated goal must be abandoned.
This whitepaper discusses:
• The problem, impact and solutions for blood culture contamination.
• What about 3% is good for the patient?
• Why are blood cultures contaminated so often?
• And more.
Magnolia Medical is committed to empowering healthcare providers with advanced technologies that virtually eliminate false-positive diagnostic results for sepsis, the associated patient safety risks, and avoidable costs to our healthcare system. Inventors of the Initial Specimen Diversion technology platform for blood culture collection and contamination prevention, the company has amassed an IP portfolio including more than 60 issued method, apparatus and design patents with over 50 additional patent applications pending.